Windlas Biotech Ltd Stock Price Today (NSE: WINDLAS)

Windlas Biotech Ltd

817.0012.15 (1.47%)
Market Open

Fundamental Score

...

Windlas Biotech Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Windlas Biotech Ltd share price today is 817.00, down 1.47% on NSE/BSE as of 17 June 2026. Windlas Biotech Ltd (WINDLAS) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 1.66K (Cr). The 52-week high for WINDLAS share price is 1097.90 and the 52-week low is 697.40. At a P/E ratio of 24.62x, WINDLAS is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 12.76% and a debt-to-equity ratio of 0.06.

Windlas Biotech Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
884.90
Low
746.55
Volume
67.4K
Change
-5.36%

Windlas Biotech Ltd share price chart: -5.36% return over the past month. 52-week high ₹1097.90, 52-week low ₹697.40.

Windlas Biotech Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
813.10828.95797.15812.3046.93K (Cr)
833.10848.00810.85813.1036.37K (Cr)
812.60852.55812.60833.1075.11K (Cr)
821.35833.00790.00819.701.93L (Cr)
793.95830.00784.10822.8584.47K (Cr)
804.95805.00770.15785.251.16L (Cr)
784.10796.90752.00789.952.00L (Cr)
807.95814.80779.00782.3558.54K (Cr)
768.90802.85760.20798.0587.34K (Cr)
779.00784.95761.00767.4032.28K (Cr)

Windlas Biotech Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
833.10848.00797.15812.30-2.50%
851.85884.90746.55833.10-2.20%
747.95898.80743.20851.85+13.89%
740.00786.00697.40736.75-0.44%
818.80928.50746.00755.00-7.79%
808.80950.00735.30848.90+4.96%
788.00818.00731.75795.05+0.89%
955.00986.00768.15783.60-17.95%
905.00963.95904.50945.50+4.48%
998.401027.50900.15905.85-9.27%
999.901097.90907.00998.40-0.15%
885.001023.05875.00989.05+11.76%

Returns & Performance

Poor

Return on Equity (ROE)

12.76%

Profit generated per ₹1 of shareholder equity

Good

Return on Capital (ROCE)

16.96%

Returns generated on total capital deployed

Good

Oper. Profit Margin (5Y Avg)

12.13%

Average operating profit margin over 5 years

Dividend Yield

0.74%

Annual dividend as % of current share price

Windlas Biotech Ltd Valuation Check

Good

Price to Earnings (P/E)

24.62x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.77x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

61.99%

% shares held by company founders/management

Poor

FII Holding

1.11%

% shares held by foreign institutional investors

Good

DII Holding

11.44%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

13.67%

Net profit growth vs same quarter last year

Good

Revenue Growth (Quarterly YoY)

18.93%

Revenue growth vs same quarter last year

Excellent

Revenue Growth (5-Year CAGR)

18.24%

Compounded annual revenue growth over 5 years

Poor

EPS Growth (5-Year CAGR)

2.83%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

30.32%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.06x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

19.07x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

78.58 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Windlas Biotech Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of WINDLAS across key market metrics for learning purposes.

Positive Indicators

10 factors identified

Excellent ROCE Performance (16.96%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Attractive Valuation (P/E: 24.62 vs Industry: 31.77)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Strong Revenue Growth (18.93%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Consistent Growth Track Record (18.24% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.

Strong Profit Growth Track Record (30.32% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Conservative Debt Levels (D/E: 0.06)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (19.07x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Strong Cash Generation (₹78.58 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Balanced Promoter Holding (61.99%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

1 factors identified

Weak Earnings Growth (2.83% CAGR)

Observation: Below-average 5-year EPS growth performance.

Analysis: Low EPS growth may not keep pace with inflation.

Windlas Biotech Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Windlas Biotech Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
62.1/100
817
₹1657.61
24.6
Average
12.76%
Average
16.96%
Good
0.1
Excellent
30.32%
Excellent
18.24%
Excellent
0.74%
65.2/100
1780
₹433738.68
37.6
Average
16.86%
Good
20.21%
Excellent
0.1
Excellent
23.78%
Excellent
9.87%
Good
0.89%
67.9/100
6597
₹170445.88
68.6
Average
15.35%
Good
20.44%
Excellent
0.0
Excellent
10.41%
Good
11.65%
Good
0.47%
65.3/100
4340
₹126430.62
58.4
Average
26.52%
Excellent
27.05%
Excellent
0.3
Excellent
13.84%
Good
7.72%
Good
0.86%
Cipla Ltd...
CIPLA500087
59/100
1399
₹123059.76
22.6
Average
17.77%
Good
22.72%
Excellent
0.0
Excellent
28.68%
Excellent
9.97%
Good
0.85%
59.2/100
1268
₹105224.96
18.2
Average
17.96%
Good
22.69%
Excellent
0.2
Excellent
22.28%
Excellent
13.26%
Good
0.63%
Lupin Ltd...
LUPIN500257
66.7/100
2250
₹95148.15
22.0
Average
20.62%
Excellent
21.30%
Excellent
0.3
Excellent
54.88%
Excellent
8.11%
Good
0.58%
68.7/100
1085
₹94253.78
18.7
Average
21.21%
Excellent
24.31%
Excellent
0.4
Excellent
25.92%
Excellent
10.27%
Good
1.17%
50.6/100
2353
₹92012.53
52.6
Average
14.68%
Average
15.98%
Good
0.6
Good
11.73%
Good
15.79%
Excellent
0.04%
28.8/100
1464
₹70798.69
20.7
Average
11.08%
Average
14.18%
Average
0.2
Excellent
3.87%
Average
6.55%
Good
0.33%
59.5/100
5277
₹67075.29
28.5
Average
19.39%
Good
20.38%
Excellent
0.2
Excellent
13.93%
Good
9.21%
Good
0.80%

Windlas Biotech Ltd PE Ratio History

Historical price-to-earnings ratio for WINDLAS — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 202528.87₹795.0527.5x
FY 202427.88₹1041.1537.3x
FY 202319.70₹428.7521.8x
FY 202218.58₹250.1013.5x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Windlas Biotech Ltd Dividend History

Annual cash dividends paid by WINDLAS — dividend yield 0.74%

Financial YearDividends Paid (₹ Cr)
FY 202511.49 Cr
FY 20248.30 Cr
FY 20237.63 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Windlas Biotech Ltd Quarterly Performance

Latest quarterly metrics for WINDLAS — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

18.93%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

13.67%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

18.24%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

30.32%

Compounded annual net profit growth over 5 years

Windlas Biotech Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for WINDLAS — calculated from daily price history

62RSI 14
Neutral — RSI 62

Momentum is balanced — neither overbought nor oversold.

SMA 50
806
▲ Price above SMA 50 — Short-term bullish
SMA 200
848
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
58K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Windlas Biotech Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Windlas Biotech Ltd (WINDLAS) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Windlas Biotech Ltd

About WINDLAS (Windlas Biotech Ltd)

Windlas Biotech Ltd is a dynamic pharmaceutical company deeply rooted in innovation and quality. Specializing in contract development and manufacturing, Windlas serves as a trusted... partner for pharmaceutical companies seeking expertise in formulation development, manufacturing excellence, and comprehensive regulatory support. The company distinguishes itself through a commitment to cutting-edge technologies and a highly skilled workforce, enabling the production of complex and specialized pharmaceutical products. Windlas is driven by a desire to meet the evolving needs of its clients and contribute to advancements in healthcare, constantly striving to deliver superior products that meet stringent quality standards and regulatory requirements. With a customer-centric approach and a focus on building lasting partnerships, Windlas is positioned as a leading player in the pharmaceutical manufacturing landscape. The company's core strength lies in its diversified product portfolio and its ability to handle complex formulations. Windlas offers a broad range of manufacturing capabilities, including solid oral dosages, modified-release formulations, and specialized dosage forms. They cater to a wide array of therapeutic areas, addressing diverse healthcare needs through their innovative product offerings. Windlas emphasizes research and development, consistently seeking to enhance its manufacturing processes, expand its product range, and develop novel drug delivery systems. This commitment to continuous improvement enables them to offer customized solutions that meet the specific requirements of each client, ensuring product differentiation and market success. Windlas's reputation is built on a foundation of unwavering adherence to international quality standards and regulatory compliance. The company's state-of-the-art manufacturing facilities are equipped with the latest technologies and are meticulously maintained to ensure optimal performance and product integrity. Windlas places a strong emphasis on data integrity, transparency, and ethical business practices. By maintaining the highest standards of quality and compliance, Windlas fosters trust among its clients, regulators, and stakeholders. The company's dedication to quality and regulatory excellence is paramount, underpinning its commitment to delivering safe, effective, and reliable pharmaceutical products to patients worldwide.

Company Details

Symbol:WINDLAS
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Ms. Komal Gupta
CFO & CEO
Mr. Ananta Narayan Panda
Company Secretary & Compliance Officer
Mr. Ashok Kumar Windlass
Whole-Time Director

Corporate Events

Recent
Ex-Dividend Date

WINDLAS Share Price: Frequently Asked Questions

What is the current share price of Windlas Biotech Ltd?

Windlas Biotech Ltd (WINDLAS) trades at ₹817.00 on NSE and BSE. Market cap ₹1.66K (Cr). Educational data only.

What is the P/E ratio of Windlas Biotech Ltd?

Windlas Biotech Ltd has a P/E of 24.62x vs industry average 31.77x.

What is the Bull Run score for Windlas Biotech Ltd?

Windlas Biotech Ltd has a Bull Run score of 62.1/100 based on 25+ financial parameters.

Does Windlas Biotech Ltd pay dividends?

Windlas Biotech Ltd has a dividend yield of 0.74%. Past dividends don't guarantee future payments.

What is the ROE of Windlas Biotech Ltd?

Windlas Biotech Ltd has ROE of 12.76%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Windlas Biotech Ltd?

Windlas Biotech Ltd has debt-to-equity of 0.06.

Is Windlas Biotech Ltd a good investment?

Bull Run gives Windlas Biotech Ltd a score of 62.1/100. This is not investment advice — consult a SEBI-registered advisor.